Table 2.
Demographic and relevant clinical information for the 91 study patients when separated on the basis of DGF versus noDGF classification in combination with eGFR values at 1 month posttransplantation.
| DGFlo | DGFhi | DGFlo versus DGFhi (P) | noDGFlo | noDGFhi | noDGFlo versus noDGFhi (P) | DGFlo versus noDGFlo (P) | DGFhi versus noDGFhi (P ) | |
|---|---|---|---|---|---|---|---|---|
| N | 13 | 12 | 16 | 50 | ||||
| Recipient age (years) | 56.2 ± 8.1 | 47.7 ± 13.1 | 0.474 | 53.3 ± 9.1 | 48.5 ± 14.7 | 0.573 | 0.928 | 0.999 |
| Recipient sex (n) [M (F)] | 10 (3) | 7 (5) | 0.286 | 11 (5) | 30 (20) | 0.375 | 0.474 | 0.582 |
| Recipient race (n) | 0.051 | 0.018 | 0.037 | |||||
| Caucasian | 1 | 1 | 7 | 10 | ||||
| African American | 12 | 10 | 8 | 37 | ||||
| Other | 0 | 1 | 1 | 3 | ||||
| Recipient hepatitis C virus status (positive) | 0 | 3 | 0 | 7 | ||||
| CMV disease (positive) | 0 | 0 | 0 | 0 | ||||
| Recipient CMV status (positive, n) | 10 | 8 | 9 | 39 | ||||
| Donor age (years) | 47.1 ± 11.7 | 38.3 ± 13.3 | 0.418 | 42.3 ± 17.7 | 37.3 ± 13.9 | 0.549 | 0.809 | 1.000 |
| Donor sex (n) [M (F)] | 9 (4) | 9 (3) | 6 (10) | 30 (20) | 0.228 | 0.092 | 0.263 | |
| Donor race (n) | 0.232 | 0.232 | 0.109 | |||||
| Caucasian | 7 | 10 | 7 | 29 | ||||
| African American | 3 | 2 | 6 | 19 | ||||
| Other | 3 | 0 | 3 | 2 | ||||
| Donor HBV antibody (positive) | 0 | 1 | 0 | 1 | ||||
| Donor hepatitis C virus antibody (positive) | 0 | 3 | 1 | 7 | ||||
| Donor CMV status (positive) | 9 | 6 | 9 | 24 | ||||
| Cold ischemia time (min) | 1,328 ± 458 | 1,208 ± 616 | 0.980 | 1,201 ± 480 | 1,209 ± 550.3 | 1.000 | 0.924 | 0.996 |
| Warm ischemia time/revascularization time (min) | 30.8 ± 8.3 | 28.3 ± 7.5 | 0.893 | 30.1 ± 6.7 | 30.6 ± 8.1 | 0.995 | 0.994 | 0.848 |
| Pump perfusion preservation time (min) | 611.5 ± 522.6 | 428.7.0 ± 511.7 | 0.904 | 500.1 ± 490.0 | 494.8 ± 496.6 | 1.000 | 0.949 | 0.999 |
| Last donor serum creatinine (mg/mL) | 1.5 ± 0.8 | 1.1 ± 0.4 | 0.223 | 0.9 ± 0.2 | 1.0 ± 0.3 | 0.941 | 0.029 | 0.999 |
| Acute rejection episodes (n) | 4 | 0 | 2 | 7 | ||||
| HLA MM-A (n) | 1 ± 1 | 1 ± 1 | 0.924 | 1 ± 1 | 2 ± 1 | 0.295 | 0.933 | 0.334 |
| HLA MM-B (n) | 2 ± 1 | 2 ± 1 | 0.871 | 1 ± 1 | 2 ± 1 | 0.541 | 0.701 | 0.811 |
| HLA MM-DR (n) | 1 ± 1 | 1 ± 1 | 1.000 | 1 ± 1 | 1 ± 1 | 0.721 | 1.000 | 0.874 |
| HLA MM total (n) | 4 ± 2 | 4 ± 2 | 1.000 | 4 ± 2 | 5 ± 1 | 0.296 | 0.997 | 0.544 |
| Panel reactive antibodies at transplant–T (%) | 40.0 ± 42.4 | 43.0 ± 44.9 | 0.997 | 33.1 ± 34.1 | 43.5 ± 35.1 | 0.791 | 0.960 | 0.989 |
| Panel reactive antibodies at transplant–B (%) | 14.7 ± 24.4 | 21.1 ± 31.1 | 0.956 | 26.0 ± 38.7 | 21.1 ± 30.1 | 0.946 | 0.767 | 1.000 |
| Serum creatinine (mg/dL) | ||||||||
| 1 month | 3.2 ± 1.9 | 1.2 ± 0.3 | <0.0001 | 1.9 ± 0.6 | 1.2 ± 0.3 | 0.013 | <0.0001 | 0.999 |
| 3 months | 2.2 ± 0.7 | 1.2 ± 0.3 | <0.0001 | 1.8 ± 0.5 | 1.3 ± 0.4 | 0.001 | 0.135 | 0.958 |
| 6 months | 2.1 ± 0.6 | 1.2 ± 0.5 | 0.001 | 1.9 ± 0.7 | 1.3 ± 0.4 | 0.001 | 0.731 | 0.983 |
| 9 months | 1.9 ± 0.4 | 1.2 ± 0.5 | 0.668 | 2.5 ± 3.3 | 1.3 ± 0.4 | 0.032 | 0.729 | 0.999 |
| 12 months | 2.5 ± 1.1 | 1.4 ± 0.6 | 0.011 | 1.6 ± 0.4 | 1.4 ± 0.8 | 0.844 | 0.048 | 1.000 |
| eGFR (mL/min) | ||||||||
| 1 month | 28.1 ± 10.6 | 70.3 ± 12.8 | <0.0001 | 38.8 ± 6.3 | 69.6 ± 19.1 | <0.0001 | 0.329 | 0.893 |
| 3 months | 38.4 ± 10.7 | 74.9 ± 20.4 | <0.0001 | 41.7 ± 9.3 | 68.0 ± 16.6 | <0.0001 | 0.942 | 0.818 |
| 6 months | 39.5 ± 11.5 | 75.1 ± 24.0 | <0.0001 | 41.1 ± 10.4 | 66.5 ± 16.0 | <0.0001 | 0.994 | 0.323 |
| 9 months | 42.4 ± 8.3 | 73.9 ± 24.0 | 0.001 | 40.5 ± 13.3 | 68.5 ± 18.4 | <0.0001 | 1.000 | 0.849 |
| 12 months | 34.3 ± 11.2 | 65.5 ± 18.8 | 0.001 | 46.3 ± 8.2 | 65.7 ± 18.4 | 0.006 | 0.386 | 0.969 |
CMV, cytomegalovirus; HBV, hepatitis B virus; MM, mismatch.
Data are averages ± SD unless otherwise stated. eGFR was calculated using the abbreviated Modification of Diet in Renal Disease formula. Statistical differences were determined by Tukey-Kramer honestly significant difference (HSD) (α = 0.05) for multiple comparison testing or by Fisher exact test.